Rapamycin (Sirolimus) Licensed by Pfizer

Catalog No.S1039

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Price Stock Quantity  
USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rapamycin (Sirolimus) Chemical Structure

Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18

Validation & Quality Control

Product Use Citation(55)

Customer Product Validation(12)

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets mTOR [1]
(HEK293 cells)
IC50 ~0.1 nM
In vitro Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29MUnDfZRwfG:6aXOgRZN{[Xl?M1jEO|ExKG6PMYe3NkBpMoHmSG1UVw>?M1jxbnBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=>MY[yOFkxODh5Mx?=
HT-29NWXI[2tKS3m2b4TvfIlkKEG|c3H5MX2xNEBvVQ>?NFHydGw4OiCqMoL1SG1UVw>?MU\Qc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl?NYPPUY4zOjR7MEC4O|M>
HT-29NEDiS2FEgXSxdH;4bYMhSXO|YYm=M4\mR|ExKG6PM1LDbVczKGh?NWraW5RITE2VTx?=M2\VbXBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6MnHVNlQ6ODB6N{O=
PC3MW\LbY5ie2ViQYPzZZk>NUnIN4c6OTByIH7NNVzJcIJ{OSCqM{XBemROW09?NHTKN4FRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhRDFyIH7NMi=>NEfEeZMzOTl5OE[4Ny=>
PC3MWPLbY5ie2ViQYPzZZk>M3XzNlExOCCwTR?=NUX0bWNmOSCqMknXSG1UVw>?Ml7LSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25?NHK1[5IzOTl5OE[4Ny=>
PC3MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfoUGp1OS53IN88US=>MmLrNUBpM4TzcmROW09?M1zzXGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?=NGCyZ4kzOTl5OE[4Ny=>
HEK293MoTKSpVv[3Srb36gRZN{[Xl?MX:xNFAhdk1?Mk\WPEBpNFPlRZpFVVORM4jyOGlvcGmkaYTzJHRRSS2rbnT1Z4VlKGSnZ4Lh[IF1cW:wIH;mJHBl[2R2IIfpeIghTUN3MDDv[kA2OCCwTR?=NX;FTlN{OjF3M{mzNFE>
BT-20M4j5WmtqdmG|ZTDBd5NigQ>?Ml\vNlAh|ryPM1H1OmROW09?NGXiNWRFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?=NUTHO|dJOjF|NUO1OVE>
U937M4LicmFvfGmkYXP0[ZJq[WxiQYPzZZk>MUm1NEDPxE1?MXm0PEBpNVzKTHcxTE2VTx?=MUnJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN?NF\OOnAzOTF2MkGwOi=>
U937M2XwcWFvfGmkYXP0[ZJq[WxiQYPzZZk>MYS1NEDPxE1?Ml72OFghcA>?MWfEUXNQNWC3dnh5TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?=MnTTNlEyPDJzME[=
U937NE\ncoZCdnSrYnHjeIVzcWGuIFHzd4F6NVTnWXBoPTBizszNNHvURYg1QCCqM2PJcGROW09?MVHEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=>NIDDfWQzOTF2MkGwOi=>
MCF-7MXvBeZRweGijZ4mgRZN{[Xl?NXn4fI03OzBibl2=Mln5OEBpM{f3OWROW09?Mo\FTY5lfWOnczDheZRweGijZ4m=M4XzNlIxODJ6MUO0
U87MGNIDFTYVMcW6jc3WgRZN{[Xl?M2OzblEh|ryPNYX5eXFnPiCqMkHhSG1UVw>?NVX2[Xl7WG:2ZX70cJkhcW6qaXLpeJMhdVSRUj3t[YRq[XSnZDDTOkBxcG:|cHjvdplt[XSrb36=MX2xPVg1QDRyNB?=
U87MGNV\EW3c2U2mwYYPlJGF{e2G7NVO0fYRbOSEQvF2=NUHYTWRKPiCqNIrKenNFVVORNGrvPVBRd3SnboTsfUBqdmirYnn0d{A1TUKSMTjUO|AqKHCqb4PwbI9zgWyjdHnvci=>NGTBb4kyQTh2OESwOC=>
U87MGMnz2T4lv[XOnIFHzd4F6MX6xJO69VQ>?M3G0bFYhcA>?MXfEUXNQM4DWcGRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:wM{PxfVE6QDR6NEC0
U87MGMUHLbY5ie2ViQYPzZZk>M2jlWlEh|ryPMYS2JIg>NVrjSnJ[TE2VTx?=NEO4V2xFd2W|IH7veEBqdmirYnn0JHAuPEWEUEGoWFM4NzR4KTDwbI9{eGixconsZZRqd25?MnzBNVk5PDh2MES=
COS7 cells expressing EGFP-HDQ74/rhebMlntRZV1d3CqYXf5JGF{e2G7M2LmVlAvOiEQvF2=MVKyOEBpNIr4OJhFVVORNXzJR2xOUW6mdXPld{BifXSxcHjh[5k>MmfpNVg{QTF7NEm=
COS7 cells expressing EGFP-LC3MUjBeZRweGijZ4mgRZN{[Xl?M1G3UFAvOiEQvF2=M1LqWVI1KGh?NGD3cI1FVVORMVTJcoR2[2W|IHH1eI9xcGGpeR?=NFfhXFgyQDN7MUm0PS=>
H4MVPGeY5kfGmxbjDBd5NigQ>?NWnMcoJXOC5{IN88US=>MX6yOEBpMWnEUXNQM4fGVWlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM>NXrLRoE5OThyMkS1PFQ>
HeLaNE\IXYFHfW6ldHnvckBCe3OjeR?=NXvpelVEOTByIH7NNWi2cpZQOzZiaB?=M3TMTGROW09?NUfuVJBMUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?MWmxO|U3OzN6NR?=
HeLaNWjzUopJTnWwY4Tpc44hSXO|YYm=NUS0WnllOTByIH7NM1nNW|M3KGh?MUPEUXNQNGS4T4JKdmS3Y3XzJGZTSiCZMkGwNWYhdXW2YX70MZVjcXG3aYTpcmMhcW62ZYLhZ5Rqd25?MYqxO|U3OzN6NR?=
HeLaNUH0UZRUTnWwY4Tpc44hSXO|YYm=M1Pa[lExOCCwTR?=MYWzOkBpNUPWZ3JrTE2VTx?=MmHHTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;uMl:zNVc2PjN|OEW=
SYFMVnGeY5kfGmxbjDBd5NigQ>?MkfaNVAxKG6PMnTNNlQhcA>?M4HIcmROW09?NXm2eW9kUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9vMnHFNVc2PjN|OEW=
SYFNHf5fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXzNVAxKG6PNIjFe5gzPCCqM2OxcmROW09?MWTJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiU2nGJINmdGy|Ml;hNVc2PjN|OEW=
HEK293TNV7VWW5YSW62aY\pdoFtKEG|c3H5M3HKWlEhdk1?NIfVXlQ1KGR?NIHjT3dFVVORNFfVboVKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=>MVKxO|Q5PTVyMR?=
HEK293TNWqxNGNCSW62aY\pdoFtKEG|c3H5NXXFV4czOSCwTR?=NXiyVZFKPCCmMX7EUXNQMVjJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?=MmTWNVc1QDV3MEG=
PBMCMofCSpVv[3Srb36gRZN{[Xl?NWrQNYY{OSCwTR?=MlXvNVQh\A>?MWXEUXNQNGK4O5RT\WS3Y3XzJGNEWjViZHXud4l1gQ>?M4fjUFE4PDh3NUCx
PBMCMXXGeY5kfGmxbjDBd5NigQ>?M4PLbFEhdk1?Mnn0NVQh\A>?M1ewN2ROW09?NXvLPIpkTG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl?MVqxO|Q5PTVyMR?=
HEK293 cellsNVu4d3p{U2mwYYPlJGF{e2G7MmjQOVAhdk1?MlXWOFUhdWmwM2XvcGROW09?M2P1[GlvcGmkaYTzJI1VV1Jia3nuZZNmKGGldHn2bZR6KHerdHigTWM2OCCxZjCwMlEhdk1?NI\iR4YyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-lucMkDISpVv[3Srb36gRZN{[Xl?M2HDdFExOCCwTR?=MlXDOEBpMmHqSG1UVw>?MmTpTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM>NXn4R405OTdzMkiyOlI>
Human mixed lymphocyteMlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELnVVQ2KG6PNVHrRZBxTE2VTx?=NX2zUYsyUUN3ME2xMlYhdk1wNV7LNG85OTZzOEW4OlU>
Lewis rat lymph node cellsNUf0fXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVT4V5FwPSEQvF2=NIOwcHVFVVORM{DUXWlEPTB;Mj62JO69VQ>?MkfSNVYyQDV6NkW=
cells from the thymus of normal BALB/c miceM1q4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITDS2YyOCCwTR?=NXjM[JFSPzJiaB?=MYXEUXNQNF3TNnNKdmirYnn0d{BtgW2yaH;wdo9tcW[ncnH0bY9vKCiOQV[pJJdqfGhiSVO1NEBw\iB|IH7NMnvzNVAxOjF7NEi=
MRK-nu-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHsSoNsUUN3ME2wMlg1PSCyTR?=MU\TRW5ITVJ?
OCUB-MNIDC[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PSRmlEPTB;NT6yOEBxVQ>?M1Hwd3NCVkeHUh?=
SF539NVToZXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTFzLk[gdG0>M1PJcHNCVkeHUh?=
ES4MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTJzLkWgdG0>NXL2[VJmW0GQR1XS
RL95-2M1;QXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPYTGhKSzVyPUGwO{BxVQ>?MX;TRW5ITVJ?
LC-2-adMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M17QbWlEPTB;NEKzJJBONIT5OJhUSU6JRWK=
DaudiNEX1SZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTR|NDDwUS=>MXrTRW5ITVJ?
NTERA-S-cl-D1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rDNWlEPTB;NESzJJBONVH2TVNPW0GQR1XS
OS-RC-2NGnt[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rLVWlEPTB;NkWyJJBOMWXTRW5ITVJ?
VA-ES-BJNVuze49GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTd{MzDwUS=>M4S3dnNCVkeHUh?=
GR-STMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnL6TWM2OD16NE[gdG0>NI\mOFVUSU6JRWK=
SW872MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTh2NjDwUS=>NGizfG5USU6JRWK=
NOS-1MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmD0TWM2OD16N{GgdG0>NG[xbllUSU6JRWK=
MC116NGW5XmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIW2clBKSzVyPUm4OUBxVQ>?M1qzR3NCVkeHUh?=
NCI-H1355NYT4OJF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\vOY5KSzVyPUGuNFEhdk1?NVjrVVJlW0GQR1XS
RPMI-8226Mk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIPwUItKSzVyPUGuNVkhdk1?Mlv2V2FPT0WU
TE-15NUXhOZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHIenZKSzVyPUGuN|Yhdk1?M1ToXnNCVkeHUh?=
Ramos-2G6-4C10NE\FXXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLrTWM2OD1zLkS2JI5ONWTsRmY1W0GQR1XS
KU812M{PYfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXETWM2OD1{LkCxJI5ONXXsPGY4W0GQR1XS
EW-1MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTJwMUegcm0>NU\oUVdYW0GQR1XS
KS-1Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILnRYRKSzVyPUKuOFUhdk1?NUnwZoV7W0GQR1XS
SK-LMS-1MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLNTWM2OD1{LkS5JI5ONYriXphqW0GQR1XS
TGBC1TKBNHrGb29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HFcGlEPTB;Mj62PUBvVQ>?NUTYXWNEW0GQR1XS
TE-6NFzHb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHi5UJBKSzVyPUKuO|chdk1?Mn\jV2FPT0WU
ETK-1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWDJR|UxRTJwOEKgcm0>NEXa[2tUSU6JRWK=
BE-13NXTFTmE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3n4fmlEPTB;Mj65PUBvVQ>?M1XuRXNCVkeHUh?=
A3-KAWNWPaUINWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPrTWM2OD1{Lkm5JI5ONX\V[GltW0GQR1XS
TE-10MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTNwMzDuUS=>NVfYT29KW0GQR1XS
DOHH-2Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3FdoNKSzVyPUOuN|Uhdk1?NVHpc2FNW0GQR1XS
ES6NUKwOFZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vKTGlEPTB;Mz60N{BvVQ>?NVHuT2pOW0GQR1XS
OPM-2NX3zXYFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvtNYgzUUN3ME20MlE2KG6PMlTnV2FPT0WU
SH-4MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUHJR|UxRTRwM{Sgcm0>M17FPHNCVkeHUh?=
NB13M4Dyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3mxfWlEPTB;ND6zOkBvVQ>?MYXTRW5ITVJ?
HUTU-80M2T0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVvJR|UxRTRwNEKgcm0>MVzTRW5ITVJ?
CCRF-CEMNX[yfGdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXrLTVZKUUN3ME20Mlk1KG6PNV30ZWxRW0GQR1XS
TGBC24TKBM2DWZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HHNmlEPTB;NT61NUBvVQ>?NYXJbWo3W0GQR1XS
697M2nyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTZwMkigcm0>Ml\4V2FPT0WU
J-RT3-T3-5NH3Bb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTZwNE[gcm0>MX\TRW5ITVJ?
KALS-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXHSfYlYUUN3ME22MlU3KG6PNXrlelY6W0GQR1XS
no-10MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3jlZWlEPTB;Nz6yPUBvVQ>?MWDTRW5ITVJ?
SK-NEP-1NFn3PJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRThwN{mgcm0>NF;3R5NUSU6JRWK=
L-540NYTNTlloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXjc|VKSzVyPUGwMlQzKG6PMX3TRW5ITVJ?
JiyoyeP-2003M1Ln[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDVUVNkUUN3ME2xNE46PCCwTR?=NUDvcIVxW0GQR1XS
HHMnPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF[5XXRKSzVyPUGxMlM6KG6PNYm2[INmW0GQR1XS
SRNFSxZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTLTGZKSzVyPUGxMlQ2KG6PM1fOVnNCVkeHUh?=
QIMR-WILMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnMSI1KSzVyPUGxMlg2KG6PMlryV2FPT0WU
A4-FukM2HGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnTNno5UUN3ME2xN{4yOiCwTR?=NX\yd|B2W0GQR1XS
CESSM{niPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7XU2NxUUN3ME2xN{4yOyCwTR?=NVu5WHFEW0GQR1XS
KE-37NHvsXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TM[2lEPTB;MU[uNFchdk1?MoHEV2FPT0WU
SK-UT-1MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2C2[WlEPTB;MU[uPFEhdk1?MnfaV2FPT0WU
SIG-M5MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3uxRWlEPTB;MUeuNlUhdk1?MXLTRW5ITVJ?
HTNW\XbJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVXJR|UxRTF5Lk[gcm0>NIPjZVBUSU6JRWK=
DELNY\jWXozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXsTWM2OD1zNz65PUBvVQ>?MVLTRW5ITVJ?
SK-PN-DWNGPrTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnntTWM2OD1{MD6yN{BvVQ>?NIXXTIFUSU6JRWK=
RPMI-8402NVizTXlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkfOTWM2OD1{MT63O{BvVQ>?M2q4fXNCVkeHUh?=
RPMI-6666NHvIZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PJT2lEPTB;MkSuOFIhdk1?M1fj[nNCVkeHUh?=
NCI-H720NV;3c20yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJ3LkSxJI5OMlXvV2FPT0WU
EW-16M2DvXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXfCNHdRUUN3ME2yOk45PyCwTR?=MmTHV2FPT0WU
BL-70NFHXPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLycpNLUUN3ME2yPE4{QCCwTR?=MWHTRW5ITVJ?
SF126MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzidoNKSzVyPUOwMlM5KG6PMVfTRW5ITVJ?
BC-1NHfXTZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rCOWlEPTB;M{GuNlYhdk1?NXOyPYtMW0GQR1XS
MHH-PREB-1NXqzO41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;mTWM2OD1|Mj60OEBvVQ>?MXPTRW5ITVJ?
A101DMmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLhTWM2OD1|Mj62NkBvVQ>?MlS4V2FPT0WU
NMC-G1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH:1foVKSzVyPUOzMlY4KG6PMn23V2FPT0WU
LB1047-RCCNUnRSodFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml3yTWM2OD1|ND62PUBvVQ>?MXTTRW5ITVJ?
EM-2MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrze2tKSzVyPUO4MlU{KG6PMle5V2FPT0WU
COLO-684MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXfQUlZ2UUN3ME2zPU45KG6PMUHTRW5ITVJ?
BeckerNInmNVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\Ub2lEPTB;NEGuNFUhdk1?NXjmTYo1W0GQR1XS
BL-41Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXLS5ROUUN3ME20N{43PiCwTR?=MU\TRW5ITVJ?
MDA-MB-134-VIM{PW[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DjOWlEPTB;NESuNFIhdk1?NX\jN4FuW0GQR1XS
L-363M17MbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{jSNWlEPTB;NESuO|Mhdk1?NEPxeZhUSU6JRWK=
ECC4MlPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoP6TWM2OD12ND63PEBvVQ>?NX7mO|JyW0GQR1XS
A388M3TrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYK3c4VHUUN3ME20OE45OiCwTR?=NXzDdGJYW0GQR1XS
HELM1S2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWPz[lRoUUN3ME20PU44QSCwTR?=NWi5bJBFW0GQR1XS
RKOMn6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHG3N5pKSzVyPUWwMlI6KG6PMVrTRW5ITVJ?
KINGS-1M4myPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITQbItKSzVyPUWxMlU2KG6PNUPw[mNPW0GQR1XS
EB-3NVX3fZdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLITGdKSzVyPUWyMlY4KG6PM{fpOXNCVkeHUh?=
ARH-77M{Lqcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEHpXJVKSzVyPUWyMlghdk1?NV\oSIRRW0GQR1XS
GCIYM1u4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzBTWM2OD13Mz60OkBvVQ>?MkLFV2FPT0WU
NCI-H1304M120c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLX[XZKSzVyPUW3MlIzKG6PM4TDcHNCVkeHUh?=
KARPAS-299NGDzXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVvJR|UxRTZzLkiyJI5OMWPTRW5ITVJ?
IA-LMM2LFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFSxfGpKSzVyPU[4MlE{KG6PM2LH[XNCVkeHUh?=
GI-1NGnyS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUK3b206UUN3ME23NE4{QSCwTR?=M3XsV3NCVkeHUh?=
TE-11NITseXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorrTWM2OD15Nz6xO{BvVQ>?MnvpV2FPT0WU
LS-411NNUL4dpYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\4UmlEPTB;N{euOVchdk1?MXPTRW5ITVJ?
no-11NIjTe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTh|LkK0JI5OM3TrPHNCVkeHUh?=
MV-4-11NXXr[4xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFLS[ItKSzVyPUizMlc{KG6PMV\TRW5ITVJ?
BV-173NFTKT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIezTI5KSzVyPUizMlk4KG6PMV;TRW5ITVJ?
CMKMoi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTh2LkG2JI5OM4\yVnNCVkeHUh?=
LC4-1NFTsfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIHvPIxKSzVyPUi2MlczKG6PM4fLRXNCVkeHUh?=
COR-L279NHPzc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXvUoxXUUN3ME24O{4zPSCwTR?=Ml3yV2FPT0WU
NCI-H209MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\LWZNFUUN3ME24O{41OSCwTR?=MkO1V2FPT0WU
RajiM3flR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjF[nhKSzVyPUi5MlczKG6PM4i3VXNCVkeHUh?=
LB996-RCCNVHTenJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTl|LkSzJI5ONV\qN4J2W0GQR1XS
NCI-H526NVn6OXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\t[G5{UUN3ME25N{42QSCwTR?=M3\YPXNCVkeHUh?=
KGNM3:1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLrcFBKSzVyPUm2MlI6KG6PMVvTRW5ITVJ?
MOLT-4M{DvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITzdVlKSzVyPUm2Mlc6KG6PNHm0S2ZUSU6JRWK=
PF-382NITjendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFr0UGdKSzVyPUm2Mlc6KG6PMWLTRW5ITVJ?
BC-3NXHDWYZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTl7LkG4JI5OM{XzeXNCVkeHUh?=
KARPAS-422NUHCcI4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzDVoRKSzVyPUGwNk4xQSCwTR?=NUHxT3RLW0GQR1XS
SBC-1NGDKVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFX1[2pKSzVyPUGwO{44PSCwTR?=NWq3U205W0GQR1XS
LC-1FNI\BPWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHnkOGNKSzVyPUGwPE4xPSCwTR?=NXu1cYVbW0GQR1XS
GB-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlv5TWM2OD1zMEmuNFIhdk1?NITkdo9USU6JRWK=
SNB75MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlX4TWM2OD1zMUmuOlkhdk1?M4LKbXNCVkeHUh?=
BB65-RCCMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTFzOT65N{BvVQ>?M3zy[3NCVkeHUh?=
NCI-N87MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXjQS49[UUN3ME2xNlEvQThibl2=NYHCTYZkW0GQR1XS
IST-MEL1Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGHoVpNKSzVyPUGyNk4{QCCwTR?=MY\TRW5ITVJ?
HOP-62MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\mTWM2OD1zMk[uPFkhdk1?Mlr0V2FPT0WU
ACNM{TOZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPTdJdKSzVyPUG0Ok44PSCwTR?=MVPTRW5ITVJ?
DMS-114NH;WdVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV21dWtyUUN3ME2xOVAvPjdibl2=NH;XOFZUSU6JRWK=
MLMANEHTNnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1O4OWlEPTB;MUW5Mlg5KG6PMVLTRW5ITVJ?
HT-144M33VT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX3JR|UxRTF4NT60N{BvVQ>?MlO4V2FPT0WU
C2BBe1M3HkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\WTWM2OD1zNkeuO|Yhdk1?MXrTRW5ITVJ?
L-428NF;CZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\3e4xCUUN3ME2xO|cvPyCwTR?=MVnTRW5ITVJ?
DU-4475MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NILkW|VKSzVyPUG4O{43QCCwTR?=NULZc4M3W0GQR1XS
CP67-MELNUD5[JhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGTMW3VKSzVyPUG5PU4{QCCwTR?=MlzVV2FPT0WU
MEG-01NVXweJVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HQZmlEPTB;MkCxMlk3KG6PNED3Oo5USU6JRWK=
IST-SL2Mke3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3fTeGlEPTB;MkC4MlY{KG6PNILZ[G9USU6JRWK=
ES8NWLvXWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWTJR|UxRTJ{NT65OEBvVQ>?MYPTRW5ITVJ?
COLO-800MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXobWttUUN3ME2yN|UvOjhibl2=M4m4R3NCVkeHUh?=
MFH-inoMlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH\6[nRKSzVyPUKzOU45PCCwTR?=Mn3ZV2FPT0WU
OVCAR-4NX[z[YpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXq5bIVGUUN3ME2yN|cvOjRibl2=NXjnS|RCW0GQR1XS
PSN1M4DqdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PoNWlEPTB;MkSyMlcyKG6PNEfuWXdUSU6JRWK=
EW-12MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTJ2Mz6xJI5OMkXKV2FPT0WU
HCC1599MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTJ4MT60O{BvVQ>?MXfTRW5ITVJ?
SJSA-1Mn3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWPJR|UxRTJ5MT60OkBvVQ>?MVLTRW5ITVJ?
ST486MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWrJR|UxRTJ7Nj6xOEBvVQ>?MYnTRW5ITVJ?
NOMO-1Ml25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX;JR|UxRTNyMD6yNUBvVQ>?MlTOV2FPT0WU
MN-60NVTqTGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTNyNT6zNkBvVQ>?M3jXdnNCVkeHUh?=
HCC1187MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzBO4E4UUN3ME2zNFcvOjVibl2=MnO0V2FPT0WU
SW982NVjDb|hST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkK5TWM2OD1|MUSuO|Uhdk1?MXfTRW5ITVJ?
LB647-SCLCNFy5eJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PR[GlEPTB;M{K4MlcyKG6PMmHMV2FPT0WU
HC-1M3:5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDvT3hyUUN3ME2zN|UvPSCwTR?=NIq3dINUSU6JRWK=
EHEBNGfOPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTN|Nz61NkBvVQ>?M4TNVnNCVkeHUh?=
TURMmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;6TWM2OD1|NkOuPVUhdk1?NVjwbnR3W0GQR1XS
LU-139M2T3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHJTWM2OD1|N{iuNFIhdk1?NWXwVIhXW0GQR1XS
NB1NInIUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XpZWlEPTB;M{i0MlQ2KG6PMmnoV2FPT0WU
BB30-HNCNYqxTHgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\CTVdKSzVyPUO4PE4{OiCwTR?=MmHwV2FPT0WU
HAL-01NUKyRpdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTN6OT6yOkBvVQ>?MWDTRW5ITVJ?
K5MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoO1TWM2OD12MUGuN|chdk1?MYHTRW5ITVJ?
MZ2-MELMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{K5ZWlEPTB;NEGzMlY1KG6PMnHuV2FPT0WU
RXF393MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2T3O2lEPTB;NEG2MlQ2KG6PMlrPV2FPT0WU
NCI-H1648M4Pl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDCTWM2OD12MUeuOVMhdk1?MofZV2FPT0WU
TE-12MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUi0e5BbUUN3ME20N|QvOjZibl2=MWHTRW5ITVJ?
EoL-1-M3:yTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1GyfGlEPTB;NEO3Mlk5KG6PNGHjfXBUSU6JRWK=
JARM2ruRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmqzTWM2OD12M{iuOlIhdk1?NH[xS5JUSU6JRWK=
DSH1NWiydo9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1\Be2lEPTB;NEW4MlkyKG6PNGfod3FUSU6JRWK=
NCI-H187MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGn1TIpKSzVyPUS2Nk45OSCwTR?=NGnYZWdUSU6JRWK=
HCE-4NIHuXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTR5Nz62OkBvVQ>?M{PwdnNCVkeHUh?=
8-MG-BAM{[3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX0NGxYUUN3ME21PFEvPTJibl2=MnLNV2FPT0WU
KLEM4frTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIe2W3pKSzVyPUW4OU4zKG6PNHexO41USU6JRWK=
KNS-42MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFW0TGNKSzVyPUW4Ok45OSCwTR?=NXi2fZVwW0GQR1XS
MSTO-211HMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{HlNmlEPTB;NkC5Mlc1KG6PMXjTRW5ITVJ?
GDM-1M1TBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLQTWM2OD14MUSuNFkhdk1?M3PGUXNCVkeHUh?=
TE-1NH3RW5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUW5U2VSUUN3ME22OFYvOTJibl2=NIG0O5RUSU6JRWK=
BT-474NUe3c5d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvhZVQ5UUN3ME22OFcvODZibl2=MoKxV2FPT0WU
KARPAS-45NG\LXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3qxVGlEPTB;NkS3MlYhdk1?MmnBV2FPT0WU
MOLT-16NXX1OmFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4rJdGlEPTB;NkS3Mlk{KG6PMY\TRW5ITVJ?
KURAMOCHIMoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHuTWM2OD14NUeuOVEhdk1?MXfTRW5ITVJ?
K-562MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkS1TWM2OD14NkmuOVEhdk1?MULTRW5ITVJ?
EKVXMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fGV2lEPTB;NkeyMlcyKG6PNHLMR5RUSU6JRWK=
GAKNX\hfXF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVvJR|UxRTZ5NT6zJI5OMl;lV2FPT0WU
NCI-SNU-5Mn;DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\GbVNQUUN3ME22PVAvODFibl2=NV7XU3B1W0GQR1XS
NCI-H2126NFuydVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3K0UWlEPTB;N{K2Mlg4KG6PNIPQS21USU6JRWK=
CTV-1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjqVIpKSzVyPUe0OE46KG6PMV;TRW5ITVJ?
SW962NWDZR2wxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnK3TWM2OD15NEiuOFQhdk1?Mn\LV2FPT0WU
MONO-MAC-6NF70N2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml\LTWM2OD15NU[uPVMhdk1?NFux[I9USU6JRWK=
NCI-H748M3\YdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXXTWM2OD15NUiuPVkhdk1?NFzt[YJUSU6JRWK=
NCI-H524NVH3elZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2mwe2lEPTB;N{iwMlc{KG6PNHLpfG5USU6JRWK=
LS-123NIHDepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHZPY5iUUN3ME23PVUvPjlibl2=NHrH[ndUSU6JRWK=
NB7MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVPJR|UxRThzND6xOEBvVQ>?NFXvTndUSU6JRWK=
LS-1034M2fDPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTh{OD65PEBvVQ>?MoqzV2FPT0WU
TE-5M4TR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHz[WRkUUN3ME24PFMvPTZibl2=NF\Ne|VUSU6JRWK=
A704NGfPRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPIOYNKSzVyPUi5PU4yPSCwTR?=NVjObWpGW0GQR1XS
TK10M{[0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XEV2lEPTB;OUG2MlA{KG6PM{TwUnNCVkeHUh?=
NCI-H345NXjT[2MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PXN2lEPTB;OUSzMlIzKG6PNV33VZdWW0GQR1XS
CGTH-W-1NHHnd5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1m1NWlEPTB;OUS4MlE{KG6PNIjhNoVUSU6JRWK=
NCI-H510ANIS0O2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILieGFKSzVyPUm4OU4yOiCwTR?=NFe4fYRUSU6JRWK=
NCI-H1963MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXMeI44UUN3ME2xMlA{Ojl{IN88US=>MY\TRW5ITVJ?
SCC-3NX;UOpVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFj2eohKSzVyPUGuNFM1OTRizszNMXLTRW5ITVJ?
EW-11M2PYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoG2TWM2OD1zLkC4O|Q{KM7:TR?=NFLFNHdUSU6JRWK=
CPC-NM3XEVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4njbWlEPTB;MT6wPFgh|ryPMYjTRW5ITVJ?
NCI-H1417M3v5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzVTWM2OD1zLkGyNlYh|ryPNUezXZlSW0GQR1XS
DG-75NWLTVlhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfNS5o5UUN3ME2xMlE3Ojh3IN88US=>MYrTRW5ITVJ?
HD-MY-ZM4LnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYXJR|UxRTFwMU[0NVYh|ryPM4PqWHNCVkeHUh?=
ATN-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWPOfFY2UUN3ME2xMlI3OjB7IN88US=>MoPYV2FPT0WU
KM-H2M{Xlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1fxSWlEPTB;MT6yOlQxQCEQvF2=NG\PVo5USU6JRWK=
NCI-H2081M4Prc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nCPWlEPTB;MT6yOlY{PyEQvF2=Mmm5V2FPT0WU
HL-60NHjkTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvpU4RKSzVyPUGuNlY6PTlizszNMYPTRW5ITVJ?
DBMlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrRTWM2OD1zLkK3NlQzKM7:TR?=MXfTRW5ITVJ?
NCI-H1522MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfyTohKSzVyPUGuNlg5QDdizszNNFSxSmhUSU6JRWK=
AM-38M{LoXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFT4N4tKSzVyPUGuN|A4OiEQvF2=M4fobXNCVkeHUh?=
NCI-H446NVmzPYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTFwM{KxNlEh|ryPMoDtV2FPT0WU
SU-DHL-1NV\QWnl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUGz[IpvUUN3ME2xMlMzQDBzIN88US=>MYnTRW5ITVJ?
NH-12NYTEVlUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXfJR|UxRTFwM{[zO|Qh|ryPMnjHV2FPT0WU
DMS-79M2jSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHGwcIpKSzVyPUGuN|Y5PjZizszNMlXvV2FPT0WU
NCI-H716NV\vS3ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmPmTWM2OD1zLkO4PVg3KM7:TR?=MWLTRW5ITVJ?
ML-2NFfwXZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTFwNEG1Nlkh|ryPNYe2bZdvW0GQR1XS
NB10Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTFwNE[2N|Ih|ryPMXzTRW5ITVJ?
ONS-76NVHQZYxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXjJR|UxRTFwNUO1Olkh|ryPM4HtfHNCVkeHUh?=
LOUCYNWLF[5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVzJR|UxRTFwNUS2OVch|ryPM{K2XHNCVkeHUh?=
SCLC-21HNYTPbZdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDrTWM2OD1zLkW4OVgzKM7:TR?=NEXiWndUSU6JRWK=
TGWMUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LiS2lEPTB;MT62N|k4PSEQvF2=NUfPNnUxW0GQR1XS
LXF-289NUXUV4YxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLEU5dlUUN3ME2xMlc{OjZ6IN88US=>NETNWpdUSU6JRWK=
BB49-HNCMnXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGf5c4xKSzVyPUGuO|M2QDZizszNMnjDV2FPT0WU
NCI-H747NIXUcpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn3DTWM2OD1zLke1N|Q3KM7:TR?=M4HvTHNCVkeHUh?=
LU-165NI\jTpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPvPZBKSzVyPUGuPFQ6QDZizszNMYPTRW5ITVJ?
OMC-1M37sO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrqSWJKSzVyPUGuPVUxPjZizszNMUnTRW5ITVJ?
RCC10RGBNYj2UY4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFGxbYlKSzVyPUGuPVU5OTdizszNMU\TRW5ITVJ?
SW684MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTFwOU[wPVkh|ryPMk[2V2FPT0WU
TE-8Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1LhTWlEPTB;Mj6wOVU2QSEQvF2=M1S0bnNCVkeHUh?=
SK-N-DZNFHnNo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzvfo1xUUN3ME2yMlE{Ojd2IN88US=>NFXjdXpUSU6JRWK=
EVSA-TMk\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEL0R5ZKSzVyPUKuNVc{OTVizszNM{nnNHNCVkeHUh?=
KASUMI-1NWjjbnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXW4dotTUUN3ME2yMlE5QDF3IN88US=>Mk\tV2FPT0WU
NKM-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3PV|dKSzVyPUKuNlU1PzJizszNNF;HPFZUSU6JRWK=
CAL-148NXzKUJdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\ETWM2OD1{LkOzOlE1KM7:TR?=MlPsV2FPT0WU
NCI-H64M2\YUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnwTWM2OD1{LkO0NlMzKM7:TR?=MXvTRW5ITVJ?
KNS-81-FDMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{f4V2lEPTB;Mj6zOlYzKM7:TR?=M2HhU3NCVkeHUh?=
KM12MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4S5NWlEPTB;Mj60NFg{QSEQvF2=M2Lob3NCVkeHUh?=
SW954MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TXXWlEPTB;Mj60O|c4QSEQvF2=NHnaZXlUSU6JRWK=
NCI-H1395NWHIclVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zqcWlEPTB;Mj61NlY1PSEQvF2=NXnuXZp7W0GQR1XS
DJM-1NVP6c254T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjETWM2OD1{Lk[wOlMh|ryPMlK1V2FPT0WU
COLO-668MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1mwcWlEPTB;Mj64NlY6PSEQvF2=M1K3RXNCVkeHUh?=
NCI-H1436M1XJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzsUlBOUUN3ME2yMlg2PjF3IN88US=>NYXYdXV1W0GQR1XS
LB2241-RCCMoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJwOE[4N|kh|ryPMV\TRW5ITVJ?
GT3TKBNUfVT3ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEKz[3lKSzVyPUKuPFkxPTVizszNNEjZNXNUSU6JRWK=
COLO-824M33mTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWjyOIppUUN3ME2yMlg6PzZ6IN88US=>NYfEbWRRW0GQR1XS
ES1MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2DySmlEPTB;Mj64PVg4QSEQvF2=MWPTRW5ITVJ?
LB771-HNCNH;qSoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzhSIxKSzVyPUKuPVA6PDZizszNMlz6V2FPT0WU
GI-ME-NM4C5dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVTJR|UxRTNwMEC5NFQh|ryPM1\3PXNCVkeHUh?=
NALM-6NXXCbZR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2DMNWlEPTB;Mz6wNFk{OyEQvF2=NHLsRXFUSU6JRWK=
LU-134-AMoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTNwMEW0NlUh|ryPNGjWU3VUSU6JRWK=
DMS-153NF\aSo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2O1UmlEPTB;Mz6wOVgzPCEQvF2=MofyV2FPT0WU
MZ1-PCNHfWU3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTNwMEmwO|gh|ryPNFu0cmNUSU6JRWK=
NCI-H1155M2q0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fBXGlEPTB;Mz6xNVYyKM7:TR?=NGTR[phUSU6JRWK=
CAS-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV;JR|UxRTNwMUO3NFch|ryPM4Lu[nNCVkeHUh?=
D-502MGNGPFVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XjR2lEPTB;Mz6xOFM6KM7:TR?=NX;PcnA1W0GQR1XS
NCI-H2141NUPwUoJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfa[WZKSzVyPUOuNVc1PTJizszNM37S[XNCVkeHUh?=
NB6NU[2Z25ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHW3e4ZKSzVyPUOuNVgzPTlizszNMVTTRW5ITVJ?
NCCITMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWDJdXUxUUN3ME2zMlIyQDB7IN88US=>NHPVWW1USU6JRWK=
NB69MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3XvUGlEPTB;Mz6zNVg6OSEQvF2=MYLTRW5ITVJ?
JVM-2MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfwWZBUUUN3ME2zMlM3PDN|IN88US=>NYXVZVNpW0GQR1XS
K052MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{OxXmlEPTB;Mz6zO|k3QCEQvF2=MWLTRW5ITVJ?
HCC2157NVLFUVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MluzTWM2OD1|LkWzNlI5KM7:TR?=NIPOR2xUSU6JRWK=
KMOE-2MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;LfZFKSzVyPUOuOVQzPDJizszNM{C5ZnNCVkeHUh?=
SF268MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTNwN{G1OVQh|ryPM1\aTHNCVkeHUh?=
CHP-126NH6yUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHRTWM2OD1|Lke2OFU5KM7:TR?=NHjpfY5USU6JRWK=
CP66-MELM{O1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DZNmlEPTB;Mz63PVA6PCEQvF2=M33yVnNCVkeHUh?=
NCI-H69M1vW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jke2lEPTB;ND6wNVk{PiEQvF2=MmPHV2FPT0WU
A253MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HFTWlEPTB;ND6wNlExOSEQvF2=NFSwR4dUSU6JRWK=
NB14NFP3T|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlPyTWM2OD12LkGwOFc6KM7:TR?=MWHTRW5ITVJ?
NCI-H1694NEfuNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTRwMUOxNVIh|ryPMUnTRW5ITVJ?
NCI-H2196Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{H3cGlEPTB;ND6xO|E3QSEQvF2=M2n6ZXNCVkeHUh?=
TE-9Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEnmRmJKSzVyPUSuNVc2QDJizszNMkLRV2FPT0WU
D-283MEDNWTFO5JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPMSFQ2UUN3ME20MlE5QDRizszNNWTwVGR7W0GQR1XS
OCI-AML2NV;jVJIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTRwMUm0PFkh|ryPNETLOGJUSU6JRWK=
D-263MGM37BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILoS3FKSzVyPUSuNlI6PjFizszNNEK2cm9USU6JRWK=
MPP-89M2XJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnOdIx4UUN3ME20MlI4OzB2IN88US=>NFLtR5RUSU6JRWK=
LAMA-84M4TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfuXZFKSzVyPUSuN|A1OjFizszNMn\sV2FPT0WU
LB373-MEL-DNIPaW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInTbVVKSzVyPUSuN|Y4QDlizszNMVzTRW5ITVJ?
UACC-257MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PGbGlEPTB;ND6zPVU{PCEQvF2=MUnTRW5ITVJ?
MC-CARMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVq1cYFrUUN3ME20MlQ{QTlizszNNFHvSlFUSU6JRWK=
COLO-320-HSRNX34eGNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;LXXJKSzVyPUSuOFQ1OjdizszNMlHEV2FPT0WU
P30-OHKNIHuOoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1SzN2lEPTB;ND62OlU5OSEQvF2=MkfSV2FPT0WU
UACC-812M13nUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\EUmlEPTB;ND62PVE3OSEQvF2=M3LIOXNCVkeHUh?=
CTB-1NY[wZ|dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTRwN{G1OVUh|ryPNWj4SWhmW0GQR1XS
ALL-PONHTVWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXfJR|UxRTRwOESwO|ch|ryPMVfTRW5ITVJ?
SK-MEL-2MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTyTWM2OD12Lki2PVU2KM7:TR?=NEOzbINUSU6JRWK=
TC-YIKMnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTRwOUe5OFIh|ryPM1fOWnNCVkeHUh?=
NCI-H1882NFG0e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnmzTWM2OD13LkCyNFAyKM7:TR?=M2H1SnNCVkeHUh?=
MHH-CALL-2MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEC0OXFKSzVyPUWuNFUxPDJizszNM3vEPHNCVkeHUh?=
U-87-MGNWXpUmc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHLfWVKSzVyPUWuNFk1PjZizszNMlTXV2FPT0WU
NCI-H1092NUnKTno6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PMZWlEPTB;NT6yOlU2PSEQvF2=NE\sVZdUSU6JRWK=
TE-441-TMmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInFZndKSzVyPUWuNlc5OiEQvF2=M{\rUnNCVkeHUh?=
SK-MEL-1NIn4ZZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7yU3JFUUN3ME21MlI6ODR2IN88US=>NHX5[YtUSU6JRWK=
EW-22MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MY\JR|UxRTVwMkm0OlYh|ryPMUTTRW5ITVJ?
MZ7-melM1TxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3vXemlEPTB;NT60NFY6OSEQvF2=M1\0[3NCVkeHUh?=
LP-1NX\3[3J7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfrZZJKSzVyPUWuOFEzQTFizszNMoK2V2FPT0WU
NCI-SNU-16NI\l[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXSc4FjUUN3ME21MlY1ODd2IN88US=>MU\TRW5ITVJ?
LU-65MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEXjTW5KSzVyPUWuO|Y{PzNizszNMmHQV2FPT0WU
CW-2NUi4[|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUOw[lBDUUN3ME21Mlg2QTV7IN88US=>M{nh[3NCVkeHUh?=
WSU-NHLNHPjW21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX73empWUUN3ME21Mlk2OTd2IN88US=>M2eyR3NCVkeHUh?=
IST-MES1M2T5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoriTWM2OD13Lkm1OFQ{KM7:TR?=MV7TRW5ITVJ?
U-266MmrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGPTe|ZKSzVyPUWuPVgzODJizszNNIDkSYNUSU6JRWK=
TALL-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYnIbJN3UUN3ME22MlE1Pjh6IN88US=>NUD4Z3AzW0GQR1XS
Calu-6M13Lb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHTwfZFKSzVyPU[uNVU{OTZizszNNYf2U5R4W0GQR1XS
MMAC-SFNX32[|BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX21N4xzUUN3ME22MlE5PTV4IN88US=>MnTKV2FPT0WU
NCI-H82NWDEXWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET3[3lKSzVyPU[uNlA1QDlizszNMVzTRW5ITVJ?
RS4-11M3GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn6xTWM2OD14LkK1PFk4KM7:TR?=NEXDT5VUSU6JRWK=
SNU-C2BNYOxPYozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LsRmlEPTB;Nj60NFk3QSEQvF2=NHLEfVNUSU6JRWK=
BOKUNGLrTnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTZwNEe1PVch|ryPMoTBV2FPT0WU
C8166NIPV[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvUTWM2OD14LkW1PVEzKM7:TR?=NGrP[XlUSU6JRWK=
D-247MGNFjtVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWj6WmhzUUN3ME23MlA1OzR5IN88US=>MnP0V2FPT0WU
EW-18MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlWwTWM2OD15LkC3NlkzKM7:TR?=NUDYeos4W0GQR1XS
KG-1MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHWZ4UyUUN3ME23MlYzPzN6IN88US=>M2\hVXNCVkeHUh?=
REHM4TBUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnYNo9KSzVyPUeuOlgyODlizszNMYTTRW5ITVJ?
U-698-MMo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7PWYdKSzVyPUeuPFQ{OTVizszNM2r0ZnNCVkeHUh?=
KP-N-RT-BM-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHnObHFKSzVyPUeuPVMxOjlizszNM1n5d3NCVkeHUh?=
MS-1NXTBfWZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zDe2lEPTB;Nz65OlA1OSEQvF2=MWDTRW5ITVJ?
SNU-C1MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHjKPItKSzVyPUeuPVgyQTJizszNNET3[4JUSU6JRWK=
SK-MM-2NXzyUpI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRThwMk[wOlUh|ryPM2\kd3NCVkeHUh?=
LAN-6M4HBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoHwTWM2OD16LkOwNFAyKM7:TR?=NXm2ZVAyW0GQR1XS
NEC8NIfBeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRThwM{C2PVEh|ryPMUDTRW5ITVJ?
NCI-H1770NXTXboxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\oTWM2OD16LkO4NFAzKM7:TR?=NW\EdI1CW0GQR1XS
D-336MGM3PwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRThwNECxNVYh|ryPNUfNTmVKW0GQR1XS
COLO-829NWTXbZo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXj2emY4UUN3ME24MlQ5QDd7IN88US=>NFXuOHZUSU6JRWK=
LS-513MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRThwNUm1PVkh|ryPMk[4V2FPT0WU
YTNH;yd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRThwNkK0Nlch|ryPNVr6c3BmW0GQR1XS
EW-24MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M13vO2lEPTB;OD63OlU1KM7:TR?=MYXTRW5ITVJ?
IST-SL1Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXS1SnRTUUN3ME24Mlg3PTR|IN88US=>M{TJWHNCVkeHUh?=
CA46M3;lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUnJR|UxRThwOUWwPVgh|ryPNWTURpNSW0GQR1XS
NCI-H1838MlL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHsTWM2OD16Lkm4OlAzKM7:TR?=M3fnTXNCVkeHUh?=
NCI-H719MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXMTWM2OD17LkK1Nlc6KM7:TR?=NUW4bmJtW0GQR1XS
HCE-TNHnSRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DkTWlEPTB;OT6zNFg2OSEQvF2=NFv4NmtUSU6JRWK=
A498MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PqXmlEPTB;OT6zOlEzPCEQvF2=Ml\lV2FPT0WU
LB831-BLCMlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTXXWRKSzVyPUmuO|Y2OjFizszNNGLyN|VUSU6JRWK=
SKM-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTlwOEW5OlMh|ryPM3;hOXNCVkeHUh?=
THP-1NWjMfos5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTlwOU[5NVgh|ryPMlSzV2FPT0WU
SHP-77M3T2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnOempKSzVyPUGwMlQxPyEQvF2=M4DPR3NCVkeHUh?=
EW-3NFnZU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVXjR5hWUUN3ME2xNE43Ojh7IN88US=>NV[1SXllW0GQR1XS
KY821NEHGV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFTaV3hKSzVyPUGwMlc3OyEQvF2=M{TIT3NCVkeHUh?=
NCI-SNU-1NVW5XXFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fqcGlEPTB;MUGuNFIyPyEQvF2=Ml[1V2FPT0WU
HCC2218MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTFzLkO5PFYh|ryPMYDTRW5ITVJ?
IM-9M{fZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfjellKSzVyPUGxMlUyODZizszNMnrwV2FPT0WU
NCI-H889NGfMSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX\xN4pYUUN3ME2xNU42OzF|IN88US=>M3P4VHNCVkeHUh?=
HDLM-2NGPmOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnCTWM2OD1zMj60NVU6KM7:TR?=NFm0OmVUSU6JRWK=
LB2518-MELMkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXtTWM2OD1zMj62PFE2KM7:TR?=M2DlUHNCVkeHUh?=
NCI-H23M3m4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnL5TWM2OD1zMz6yOFI2KM7:TR?=MWrTRW5ITVJ?
NB17NVq2TmJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGHGN2pKSzVyPUGzMlQ2PzlizszNNGjpdINUSU6JRWK=
NCI-H322MMorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHm3S3dKSzVyPUG0MlQxPjhizszNNHX4fotUSU6JRWK=
SUP-T1NEfLNJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\XTnZFUUN3ME2xOE41OTNizszNMUDTRW5ITVJ?
ES3NVv1NGI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmXqTWM2OD1zNT6wO|A{KM7:TR?=NWf1SIMxW0GQR1XS
ES5MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrWRpNOUUN3ME2xOU4xPzh5IN88US=>NGjRVHVUSU6JRWK=
NCI-H1650M3r5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTF3LkS5O|kh|ryPM2DiOHNCVkeHUh?=
NCI-H226M4HB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\XdGlEPTB;MUWuPFc3QCEQvF2=NV\JWGNXW0GQR1XS
COR-L88M17keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX1c3hiUUN3ME2xOk4{OTRizszNM{LVWHNCVkeHUh?=
SCC-15M3PBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;HfHFuUUN3ME2xOk4{QDZ7IN88US=>Mn24V2FPT0WU
GOTOMnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHxTWM2OD1zNj60O|k{KM7:TR?=NV3DSVBTW0GQR1XS
SIMANWLkPHFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX0UYpKSzVyPUG2MlQ5ODJizszNM2PmNHNCVkeHUh?=
NCI-H1299M1TpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEfH[nJKSzVyPUG3MlE2QTFizszNM2\lWnNCVkeHUh?=
NCI-H1581NIDEZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3nOUGlEPTB;MUeuOFIyQSEQvF2=M{DHeXNCVkeHUh?=
MHH-NB-11MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfVSIQzUUN3ME2xO{46Pjh|IN88US=>MknHV2FPT0WU
MFM-223NGLwT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NInWToNKSzVyPUG4MlA2OzhizszNMm\MV2FPT0WU
ES7NIPQbVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2f1N2lEPTB;MUiuOVQ{OSEQvF2=MXPTRW5ITVJ?
JVM-3MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTF6LkexO{DPxE1?M2m3ZXNCVkeHUh?=
RLM4nyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEKySoJKSzVyPUKwMlM5QCEQvF2=MnyyV2FPT0WU
EC-GI-10NYPXdWFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHu3ZY5KSzVyPUKxMlIxPDFizszNNGfMdIxUSU6JRWK=
LNCaP-Clone-FGCNEjMUZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTJzLk[3Olgh|ryPNYGwOmxKW0GQR1XS
IMR-5NHvYXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvNbG9RUUN3ME2yNU45PDl2IN88US=>MUTTRW5ITVJ?
KP-N-YSMl3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUf0OGc3UUN3ME2yNU45PzVizszNNEjhWoFUSU6JRWK=
Mo-TNXHlS2c6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDiUnRrUUN3ME2yNk4zOTh3IN88US=>NETpclBUSU6JRWK=
NCI-H128NYLFW4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33v[GlEPTB;MkOuOVg2OyEQvF2=MX3TRW5ITVJ?
RH-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXlblhKSzVyPUKzMlc5PjZizszNNE\sWGJUSU6JRWK=
NCI-H2171M3;P[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTJ2LkK0PFUh|ryPMVfTRW5ITVJ?
RPMI-8866NUDmPFdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUW1[XduUUN3ME2yOk44PDJizszNMWXTRW5ITVJ?
SK-N-FINYrycFdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFm1RYRKSzVyPUK3MlM5OTFizszNNGL2OHlUSU6JRWK=
LOXIMVIM4nOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4O0eWlEPTB;MkeuPFA2OSEQvF2=NHzmeopUSU6JRWK=
P31-FUJNV74bHdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUnJR|UxRTNzLkWzO|Qh|ryPMkH3V2FPT0WU
KMS-12-PENYjxPGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH25cpNKSzVyPUS5MlU{ODJizszNMU\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

Cell Assay:

[3]

Cell lines U87-MG, T98G, and U373-MG
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

Animal Study:

[7]

Animal Models Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
Formulation Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
Dosages ~4 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.

[2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-05-07)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02487485 Not yet recruiting Depression Yale University August 2016 Phase 1
NCT02642094 Not yet recruiting Cancer of Breast The University of Texas Health Science Center at San Antonio July 2016 Phase 0
NCT02567435 Not yet recruiting Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle  ...more Alveolar Rhabdomyosarcoma|Botryoid-Type Embryonal Rhabdomyosarcoma|Embryonal Rhabdomyosarcoma|Rhabdomyosarcoma|Sclerosing Rhabdomyosarcoma|Spindle Cell Rhabdomyosarcoma|Untreated Childhood Rhabdomyosarcoma National Cancer Institute (NCI) June 2016 Phase 3
NCT02753309 Not yet recruiting Bladder Cancer The University of Texas Health Science Center at San Antonio May 2016 Phase 0

view more

Chemical Information

Download Rapamycin (Sirolimus) SDF
Molecular Weight (MW) 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AY 22989,NSC-2260804
Solubility (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Customer Product Validation (12)


Click to enlarge
Rating
Source Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines Persister cells
Concentrations 10 nM
Incubation Time 3 days
Results While added with a specific mTOR inhibitor, rapamycin(Rapa), it inhibitied endogenous mTOR activity, showed that markedly reduced MYC protein levels in persister cells but not in naive T-ALL cells.

Click to enlarge
Rating
Source Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck
Method Cell viability Analysis
Cell Lines Ar+murine (CaP8) and human (LNCaP) prostate cancer cells, Pb-Cre+;PtenL/L mice, Pb-Cre+;PtenL/L;ArL/Y mice
Concentrations 1 nM, 4 mg/kg
Incubation Time 0-4 weeks
Results These data suggest that CaPs with AR loss have greater reliance upon the PI3K/AKT/mTOR-signaling pathways and that combined AR/androgen blockage in conjunction with PI3K/AKT/mTOR inhibition (by Rapamycin) is more effective for CaPs initiated by PTEN loss or PI3K/AKT activation.

Click to enlarge
Rating
Source Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck
Method EdU labeling
Cell Lines MCF-7 cells
Concentrations 150 nM
Incubation Time 48 h
Results The punctate structures from SRC-3 or MIF knockdown cells are very similar to that found in cells treated with rapamycin, a known inducer of autophagy.

Click to enlarge
Rating
Source Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck
Method Cell imaging
Cell Lines H4-LC3-GFP cells
Concentrations 200 nM
Incubation Time 24 h
Results Consistent with inhibition of autophagy, the levels of LC3-II were lower and the levels of SQSTM1/p62 were higher in this USP18 knockdown cell line compared to that of control under basal conditions as well as the induced condition after the treatment with rapamycin.

Click to enlarge
Rating
Source Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 250 nM
Incubation Time 24 h
Results Rapamycin virtually abolishes stimulation by Rheb of phospho-S6 kinase and phospho-4EBP1 but has negligible effects on phospho-eIF2a (A). In contrast to phosphorylation of eIF2a, which is not mediated by mTORC1, phosphorylation of other elongation factors does involve mTORC1. Thus, rapamycin prevents phosphorylation of eIF4G and eIF4B, targets of S6K, but not eIF2a (B). By contrast, rapamycin, as expected, abolishes phospho-S6 kinase but fails to influence phospho-eIF2a, phospho-Erk or phospho-Akt (C).

Click to enlarge
Rating
Source Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck
Method Immunofluorescence
Cell Lines RAW264.7 cells
Concentrations 10 uM
Incubation Time 16 h
Results It has been reported that autophagy can directly regulate inflammatory responses. To confirm this phenomenon, we pre-treated RAW264.7 cells with 3-MA (an autophagy inhibitor by blocking the class III PI3Ks) or rapamycin (an autophagy inducer by targeting the negative regulators against autophagy as mammalian target of rapamycin (mTOR)), followed by addition of LPS. LPS-induced punctate LC3 was markedly reduced and enhanced in the presence of 3-MA and rapamycin, respectively.

Click to enlarge
Rating
Source Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines H1299 cells
Concentrations 2 μM
Incubation Time 48 h
Results RAD001 and other mTOR inhibitors decreased the levels of survivin protein, as assessed by Western blot analysis, without affecting the levels of other IAP members. In addition, combined treatment with sorafenib and mTOR inhibitor Rapamycin and RAD001 decreased survivin expression to a greater extent than treatment with either alone.

Click to enlarge
Rating
Source J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck
Method Histological analysis, immunohistochemistry, Liver triglyceride content analysis, real-time PCR
Cell Lines Male SD rats
Concentrations
Incubation Time 7 d
Results To determine the effect of rapamycin, an mTOR inhibitor, in the OA-induced fatty liver, rats were fed 1% OA and administered rapamycin for seven days. OA-induced lipid accumulation was completely inhibited by the treatment with rapamycin (Fig. A). HE and Oil Red O staining of liver sections clearly confi rmed the results (Fig. B). Immunohistochemistry analyses showed signifi cantly repressed SREBP-1 in the rapamycin-cotreatment liver ( Fig. B ). All the downstream effectors of SREBP-1, such as Lxr-α, Acc, Scd-1 and Fas, were consistently suppressed by rapamycin ( Fig. C ).

Click to enlarge
Rating
Source Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck
Method Measurement of cytosolic free Ca2+concentration ([Ca2+]c )
Cell Lines Human platelets
Concentrations 500 nM
Incubation Time 30 min
Results Rapamycin administration significantly reduced TG-evoked Ca2+ -entry by 19. 5 ?9.4 %.

Click to enlarge
Rating
Source Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck
Method Microscope imaging
Cell Lines NCI-H1299 cells
Concentrations 10 uM
Incubation Time 48 h
Results Growth inhibition induced by rapamycin or erlotinib is enhanced by combination treatment with monensin in NCI-H1299 cells.

Click to enlarge
Rating
Source 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck
Method Western Blot
Cell Lines HeLa cells
Concentrations 0/2/20/200 nM
Incubation Time 24 h
Results

Click to enlarge
Rating
Source 2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck
Method Western blot
Cell Lines
Concentrations
Incubation Time 0-6 h
Results Rapamycin inhibits growth-dependent TCTP induction.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus) price | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) solubility dmso | Rapamycin (Sirolimus) purchase | Rapamycin (Sirolimus) manufacturer | Rapamycin (Sirolimus) research buy | Rapamycin (Sirolimus) order | Rapamycin (Sirolimus) mouse | Rapamycin (Sirolimus) chemical structure | Rapamycin (Sirolimus) mw | Rapamycin (Sirolimus) molecular weight | Rapamycin (Sirolimus) datasheet | Rapamycin (Sirolimus) supplier | Rapamycin (Sirolimus) in vitro | Rapamycin (Sirolimus) cell line | Rapamycin (Sirolimus) concentration | Rapamycin (Sirolimus) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us